Magnetar Financial LLC Crispr Therapeutics Ag Transaction History

Magnetar Financial LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$45.39 - $59.0 $316,413 - $411,289	6,971 Added 92.18%	14,533 $659,000
Q1 2023 May 15, 2023	SELL	$41.0 - $56.12 $76,752 - $105,056	-1,872 Reduced 19.84%	7,562 $342,000
Q4 2022 Feb 14, 2023	SELL	$39.19 - $65.67 $121,175 - $203,051	-3,092 Reduced 24.68%	9,434 $383,000
Q3 2022 Nov 14, 2022	SELL	$61.1 - $83.78 $33,299 - $45,660	-545 Reduced 4.17%	12,526 $819,000
Q2 2022 Aug 15, 2022	BUY	$43.23 - $73.83 $226,352 - $386,573	5,236 Added 66.83%	13,071 $794,000
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $416,743 - $620,845	7,835 New	7,835 $492,000

489

57.9M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.16B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Magnetar Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Magnetar Financial LLC with notifications on news.